amg-837 profile

AMG-837: GPR40 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	46854655
CHEMBL ID	1829173
SCHEMBL ID	12194429
MeSH ID	M0557377

Synonym
amg-837
CHEMBL1829173 ,
bdbm50362690
AKOS016009081
amg837
amg 837
gtpl6485
(3s)-3-[4-({3-[4-(trifluoromethyl)phenyl]phenyl}methoxy)phenyl]hex-4-ynoic acid
CS-3278
HY-13967
865231-46-5
NE6U6R66U4 ,
benzenepropanoic acid, .beta.-1-propyn-1-yl-4-((4'-(trifluoromethyl)(1,1'-biphenyl)-3-yl)methoxy)-, (.beta.s)-
unii-ne6u6r66u4
SCHEMBL12194429
(s)-3-(4-((4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)hex-4-ynoic acid
AC-30223
DTXSID00676764
(3s)-3-(4-{[4'-(trifluoromethyl)[biphenyl]-3-yl]methoxy}phenyl)-4-hexynoic acid
mfcd23703041
NCGC00386948-01
AS-51920
zopnbmmvvzrsgh-nrfanrhfsa-n
Q27074441
(3s)-3-(4-{[4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl]methoxy}phenyl)hex-4-ynoic acid
EN300-313172
(3s)-3-[4-[[3-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]hex-4-ynoic acid
EX-A1792
P13904
NCGC00386948-02
Z2289809643

Excerpt	Reference	Relevance
" A potent, orally bioavailable small molecule GPR40 agonist is hypothesized to be an effective antidiabetic posing little or no risk of hypoglycemia."	( Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist. Brown, SP; Dransfield, PJ; Guo, Q; Houze, JB; Jiao, X; Li, F; Lin, DC; Liu, J; Luo, J; Medina, JC; Pattaropong, V; Sun, Y; Swaminath, G; Vimolratana, M; Wong, S; Zhang, J; Zhu, L; Zhuang, R, 2012)	0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The improvement in glucose excursions persisted following daily dosing of AMG 837 for 21-days in Zucker fatty rats."	( AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. Chen, JL; Chen, M; Houze, JB; Li, F; Li, XN; Lin, DC; Lin, YJ; Lopez, E; Lu, JY; Luo, J; Nguyen, K; Reagan, JD; Swaminath, G; Tang, L; Tian, H; Tonn, GR; Tran, T; Zhang, J; Zhuang, R, 2011)	0.37
" The dose-response relationship studies suggested that the pan agonist 15 suppressed the excursion of blood glucose levels in a dose-dependent manner."	( Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ. Deng, F; Li, Y; Li, Z; Zhang, D; Zhang, L; Zhou, Z, 2018)	0.48

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Free fatty acid receptor 1	Homo sapiens (human)	Ki	0.0219	0.0022	0.0508	0.2188	AID1308063; AID1734870
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	24.1500	0.0040	2.9266	9.9600	AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	24.1500	0.0002	2.4585	9.9600	AID1805801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Free fatty acid receptor 1	Homo sapiens (human)	EC50 (µMol)	0.5683	0.0003	0.7369	8.8000	AID1154881; AID1154882; AID1271404; AID1271405; AID1271406; AID1308064; AID1308067; AID1324909; AID1326120; AID1328827; AID1422548; AID1734871; AID1734873; AID1734879; AID620370; AID692589; AID748343
Free fatty acid receptor 1	Homo sapiens (human)	Kd	0.0019	0.0019	0.0058	0.0119	AID1734881
Cytochrome P450 2D6	Homo sapiens (human)	EC50 (µMol)	0.0022	0.0002	0.8276	4.4400	AID1326120
Free fatty acid receptor 1	Mus musculus (house mouse)	EC50 (µMol)	0.0073	0.0015	0.0105	0.0190	AID1734875; AID640066
Free fatty acid receptor 1	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0131	0.0032	0.0353	0.0990	AID1734877; AID640065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
phospholipase C-activating G protein-coupled receptor signaling pathway	Free fatty acid receptor 1	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Free fatty acid receptor 1	Homo sapiens (human)
insulin secretion	Free fatty acid receptor 1	Homo sapiens (human)
negative regulation of interleukin-1 beta production	Free fatty acid receptor 1	Homo sapiens (human)
glucose homeostasis	Free fatty acid receptor 1	Homo sapiens (human)
positive regulation of calcium ion transport	Free fatty acid receptor 1	Homo sapiens (human)
response to fatty acid	Free fatty acid receptor 1	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Free fatty acid receptor 1	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Free fatty acid receptor 1	Homo sapiens (human)
positive regulation of insulin secretion	Free fatty acid receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Free fatty acid receptor 1	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor activity	Free fatty acid receptor 1	Homo sapiens (human)
lipid binding	Free fatty acid receptor 1	Homo sapiens (human)
bioactive lipid receptor activity	Free fatty acid receptor 1	Homo sapiens (human)
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Free fatty acid receptor 1	Homo sapiens (human)
plasma membrane	Free fatty acid receptor 1	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (128)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156	DAPI mCherry counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158	ZIKV-mCherry secondary qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347157	Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1337119	Displacement of [3H](2S,3R)-3-((R)-2-(2'-fluoro-5'-methoxybiphenyl-4-yl)chroman-7-yl)-2-methylbutanoic acid from human GPR40 expressed in CHO-K1 cell membranes incubated for 30 mins on orbital shaker measured after 16 hrs by TopCount scintillation countin	2017	ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2	Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
AID640069	Agonist activity at GPR41	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1328817	Half life in iv or po dosed rat	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1326120	Agonist activity at human GPR40 expressed in HEK293 cells measured after 18 to 20 hrs by beta-gal based luciferase reporter gene assay
AID1328816	Half life in iv or po dosed dog	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1734999	AUC in hyperglycemic Balb/c mouse plasma at 1 mg/kg measured upto 60 mins	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1734869	Agonist activity at GPR40 in Sprague-Dawley rat pancreatic islets assessed as induction of glucose-mediated insulin secretion measured after 90 mins in EBSS buffer by ELISA	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1337118	Displacement of [3H]L358 from human GPR40 expressed in CHO-K1 cell membranes incubated for 30 mins on orbital shaker measured after 16 hrs by TopCount scintillation counting method	2017	ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2	Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
AID1590246	Hypoglycemic activity in Sprague-Dawley rat assessed as reduction in blood glucose AUC at 0.3 mg/kg, po pretreated for 1 hr followed by glucose challenge by OGTT relative to control	2019	Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14	Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.
AID1734884	Hypoglycemic activity in Balb/c mouse assessed as effective dose causing reduction in blood glucose level administered orally 60 mins prior to glucose challenge measured for 60 mins by IPGTT	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1328827	Agonist activity at GPR40 (unknown origin) by calcium flux assay	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1328814	Clearance in iv or po dosed monkey	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID640068	Induction of insulin secretion in mouse MIN6 cells	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640075	Antidiabetic activity in wild type mouse assessed as reduction in plasma glucose excursion at 10 mg/kg, po pretreated 60 mins before glucose challenge measured for 2 hrs by oral glucose tolerance test	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1328815	Half life in iv or po dosed mouse	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID640169	AUC in cynomolgus monkey at 0.5 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID692589	Agonist activity at GPR40 expressed in CHO cells after 20 seconds by aequorin bioluminescence assay in presence of 0.1 % human serum	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID1734880	Agonist activity at human recombinant full length GPR40 overexpressed in human HEK293 cells assessed as increase in inositol phosphate accumulation in presence of terbium cryptate-labeled anti IP1/d2-labelled IP1 measured after 120 mins by HTRF assay rela	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1734881	Displacement of [3H]-(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid from human recombinant full-length GPR40 expressed in human HEK293 cell membrane assessed as dissociation constant m	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID640067	Partial agonist activity at human GPR40 expressed in CHO cells assessed as calcium flux by aequorin assay relative to docosahexaenoic acid	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640165	Oral bioavailability in cynomolgus monkey at 0.5 mg/kg	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640080	Clearance in cynomolgus monkey at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640082	Half life in rat at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1734882	Displacement of [3H]-(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid from human recombinant full-length GPR40 expressed in human HEK293 cell membrane assessed as residence time by radio	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1590182	Positive allosteric modulation of recombinant human GPR40 expressed in HEK293 cells assessed as increase in [3H]-myo-inositol phosphate accumulation measured after 60 mins in absence of human serum by microbeta counting method relative to control	2019	Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14	Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.
AID692593	Agonist activity at GPR40 expressed in CHO cells assessed as intrinsic efficacy after 20 seconds by aequorin bioluminescence assay in presence of 0.1 % human serum relative to AM-1638	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID640167	AUC in rat at 0.5 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640171	Cmax in rat at 0.5 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1328811	Clearance in iv or po dosed mouse	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID640077	Clearance in mouse at 0.8 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID692592	Partial agonist activity at GPR40 expressed in CHO cells after 20 seconds by aequorin bioluminescence assay relative to DHA	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID640071	Agonist activity at PPAR-alpha by cell-based assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1734874	Agonist activity at human recombinant full-length Prolink-tagged GPR40 fused with EA-tagged beta-arrestin expressed in human HEK293 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by beta-galactosidase based PathHunter assa	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1328820	Oral bioavailability in rat	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID640073	Agonist activity at PPAR-gamma by cell-based assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1154886	Oral bioavailability in rat at 2 mg/kg	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Optimization of GPR40 Agonists for Type 2 Diabetes.
AID1734905	Drug distribution in C57BL/6 mouse spleen at 3 microg/kg, iv administered as single dose observed at 20 to 40 mins by LC-MS/MS analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1734870	Displacement of [3H]-TAK-875 from human recombinant full-length GPR40 expressed in human HEK293 cell membrane incubated for 2 hrs by solid scintillation counting method	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1271404	Partial agonist activity at human GPR40 expressed in CHO cells measured over 20 secs interval by luminometric analysis	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Discovery of the imidazole-derived GPR40 agonist AM-3189.
AID1734879	Agonist activity at human recombinant full length GPR40 overexpressed in human HEK293 cells assessed as increase in inositol phosphate accumulation in presence of terbium cryptate-labeled anti IP1/d2-labelled IP1 measured after 120 mins by HTRF assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1154881	Agonist activity at human GPR40 expressed in CHO cells by aequorin assay	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Optimization of GPR40 Agonists for Type 2 Diabetes.
AID692628	Antidiabetic activity in DIO BDF mouse model assessed as increase in plasma insulin level at 60 mg/kg, po administered 1 hr prior glucose-challenge challenge measured after 1 hr by ELISA	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID1328821	Oral bioavailability in dog	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1734875	Agonist activity at Prolink-tagged mouse GPR40 fused with EA-tagged beta-arrestin expressed in human U2OS cells assessed as induction of beta-arrestin recruitment measured after 90 mins by beta-galactosidase based PathHunter assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1154883	Clearance in rat at 0.5 mg/kg, iv	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Optimization of GPR40 Agonists for Type 2 Diabetes.
AID1422548	Agonist activity at FFA1 (unknown origin)	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
AID1734899	Protein binding in plasma (unknown origin) by equilibrium dialysis method	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID640076	Antidiabetic activity in GPR40 knockout mouse assessed as reduction in plasma glucose excursion at 10 mg/kg, po pretreated 60 mins before glucose challenge measured for 2 hrs by oral glucose tolerance test	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID748342	Agonist activity at human FFA1 receptor expressed in CHO cell membranes after 4 hrs by aequorin bioluminescence assay relative to AM-1638	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
AID1734909	Protein binding in C57BL/6 mouse plasma at 3 microg/kg, iv by LC-MS/MS analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1154885	Volume of distribution at steady state in rat	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Optimization of GPR40 Agonists for Type 2 Diabetes.
AID1734906	Drug distribution in C57BL/6 mouse colon at 3 microg/kg, iv administered as single dose observed at 20 to 40 mins by LC-MS/MS analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID640174	Antidiabetic activity in wild type mouse assessed as reduction of total glucose AUC at 10 mg/kg, po pretreated 60 mins before glucose challenge measured for 2 hrs by oral glucose tolerance test	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID620370	Agonist activity at human FFA1 receptor expressed in human 1321N1 cells assessed as calcium mobilization by fluorescence spectrophotometry	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
AID748343	Agonist activity at human FFA1 receptor expressed in CHO cell membranes after 4 hrs by aequorin bioluminescence assay	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
AID640083	Half life in Beagle dog at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1308065	Agonist activity at human C-terminal eYFP-tagged FFA1 receptor expressed in HEK-293 cells assessed as beta-arrestin2 recruitment incubated for 5 mins by BRET assay relative to TUG-770	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID1734900	Displacement of [3H]-MuCi from PPARalpha (unknown origin) expressed in baculovirus infected Sf9 insect cells upto 30 uM measured after 10 hrs by microbeta scintillation counting analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1328813	Clearance in iv or po dosed dog	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1734901	Displacement of [3H]-MuCi from PPARdelta (unknown origin) expressed in baculovirus infected Sf9 insect cells upto 30 uM measured after 10 hrs by microbeta scintillation counting analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID640078	Clearance in rat at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640081	Half life in mouse at 0.8 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1271430	Induction of insulin release in human pancreatic islets	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Discovery of the imidazole-derived GPR40 agonist AM-3189.
AID1734883	Agonist activity at GPR40 in mouse MIN6 cells assessed as induction of glucose-mediated insulin secretion incubated for 2 hrs by ELISA	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1328818	Half life in iv or po dosed monkey	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1271406	Partial agonist activity at human GPR40 expressed in CHO cells measured over 20 secs interval by luminometric analysis in presence of 100% human serum	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Discovery of the imidazole-derived GPR40 agonist AM-3189.
AID640168	AUC in Beagle dog at 2 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1308067	Agonist activity at FFA1 receptor (unknown origin) expressed in human 132N1 cells measured for 90 secs by Fura-2 AM dye based calcium mobilization assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID640091	Oral bioavailability in Beagle dog at 2 mg/kg	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1734878	Agonist activity at Prolink-tagged rat GPR40 fused with EA-tagged beta-arrestin expressed in human U2OS cells assessed as induction of beta-arrestin recruitment measured after 90 mins by beta-galactosidase based PathHunter assay relative to control	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID640085	Volume of distribution at steady state in mouse at 0.8 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1328819	Oral bioavailability in mouse	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID640072	Agonist activity at PPAR-delta by cell-based assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640173	Cmax in cynomolgus monkey at 0.5 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640170	Cmax in mouse at 5 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1324909	Agonist activity at FFA1 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
AID640086	Volume of distribution at steady state in rat at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1734873	Agonist activity at human recombinant full-length Prolink-tagged GPR40 fused with EA-tagged beta-arrestin expressed in human HEK293 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by beta-galactosidase based PathHunter assa	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1308063	Displacement of 3-(2-Fluoro-4-((2'-methyl-4'-(2-(2-((7-nitrobenzo[c][1,2,5]-oxadiazol-4-yl)amino)ethoxy)ethoxy)-[1,1'-biphenyl]-3-yl)-methoxy)phenyl)propanoic acid from N-terminal NLUC-tagged FFA1 receptor (unknown origin) expressed in human Flp-In T-REX-	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID640066	Agonist activity at mouse GPR40	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID692629	Antidiabetic activity in DIO BDF mouse model assessed as improvement in glucose-challenge AUC(0 to 60 mins) at 60 mg/kg, po administered 1 hr prior glucose-challenge challenge measured after 1 hr by OGTT	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID1734871	Agonist activity at human recombinant full length GPR40 overexpressed in human HEK293 cells assessed as increase in intracellular calcium level measured over 3 mins by calcium 4 dye based FLIPR assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1271405	Partial agonist activity at human GPR40 expressed in CHO cells measured over 20 secs interval by luminometric analysis in presence of 0.01% human serum albumin	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Discovery of the imidazole-derived GPR40 agonist AM-3189.
AID1337110	Positive allosteric modulation of human GPR40 expressed in HEK293 cells assessed as IP1 accumulation measured after 60 mins in presence of 100% human serum by HTRF assay relative to DMSO control	2017	ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2	Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
AID640065	Agonist activity at rat GPR40	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1734877	Agonist activity at Prolink-tagged rat GPR40 fused with EA-tagged beta-arrestin expressed in human U2OS cells assessed as induction of beta-arrestin recruitment measured after 90 mins by beta-galactosidase based PathHunter assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1308064	Agonist activity at human C-terminal eYFP-tagged FFA1 receptor expressed in HEK-293 cells assessed as beta-arrestin2 recruitment incubated for 5 mins by BRET assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID1328822	Oral bioavailability in monkey	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID1154884	Mean residence time in rat	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Optimization of GPR40 Agonists for Type 2 Diabetes.
AID1734876	Agonist activity at Prolink-tagged mouse GPR40 fused with EA-tagged beta-arrestin expressed in human U2OS cells assessed as induction of beta-arrestin recruitment measured after 90 mins by beta-galactosidase based PathHunter assay relative to control	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1328812	Clearance in iv or po dosed rat	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
AID640074	Inhibition of alpha2 adrenergic receptor	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640166	AUC in mouse at 5 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1734872	Agonist activity at human recombinant full length GPR40 overexpressed in human HEK293 cells assessed as increase in intracellular calcium level measured over 3 mins by calcium 4 dye based FLIPR assay relative to 100 uM linoleic acid	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID1734902	Displacement of [3H]-MuCi from PPARgamma (unknown origin) expressed in baculovirus infected Sf9 insect cells upto 30 uM measured after 10 hrs by microbeta scintillation counting analysis	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
AID640090	Oral bioavailability in rat at 0.5 mg/kg	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1154882	Agonist activity at human GPR40 expressed in mouse A9 cells by inositol phosphate accumulation assay	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Optimization of GPR40 Agonists for Type 2 Diabetes.
AID748325	Binding affinity to human FFA1 receptor expressed in CHO cell membranes assessed as inhibition of specific binding of [3H]AMG 837	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
AID640088	Volume of distribution at steady state in cynomolgus monkey at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640087	Volume of distribution at steady state in Beagle dog at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID692591	Partial agonist activity at GPR40 expressed in CHO cells after 20 seconds by aequorin bioluminescence assay	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID640079	Clearance in Beagle dog at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID692626	Antidiabetic activity in DIO BDF mouse model assessed as reduction in blood glucose-challenge excursion at 60 mg/kg, po administered 1 hr prior glucose-challenge challenge measured after 1 hr by OGTT ( Rvb = 462 mg/dl )	2012	ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9	Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
AID1308068	Agonist activity at FFA1 receptor (unknown origin) expressed in human 132N1 cells measured for 90 secs by Fura-2 AM dye based calcium mobilization assay relative to TUG-770	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
AID640084	Half life in cynomolgus monkey at 0.5 mg/kg, iv	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640070	Agonist activity at GPR43	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640089	Oral bioavailability in mouse at 5 mg/kg	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID640172	Cmax in Beagle dog at 2 mg/kg, po	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	AMG 837: a potent, orally bioavailable GPR40 agonist.
AID1805801	Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1345809	Human FFA1 receptor (Free fatty acid receptors)	2012	Molecular pharmacology, Nov, Volume: 82, Issue:5	Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	20 (83.33)	24.3611
2020's	4 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (91.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
catechin [no description available]	2.31	1	hydroxyflavan
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate [no description available]	2.31	1	catechin
theophylline [no description available]	2.31	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.13	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
bronopol [no description available]	2.31	1	nitro compound
caffeine [no description available]	2.31	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester [no description available]	2.31	1	leucine derivative
carmofur [no description available]	2.31	1	organohalogen compound; pyrimidines
disulfiram [no description available]	2.31	1	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.31	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	2.31	1	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.31	1	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.06	1	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	2.31	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
lauric acid dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.	2.13	1	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; antibacterial agent; plant metabolite
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.31	1	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	2.31	1	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.13	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protoporphyrin ix protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.	2.31	1
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.31	1	indoles
alkannin [no description available]	2.31	1	naphthoquinone
triclosan [no description available]	2.31	1	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	2.07	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
pyromellitic acid pyromellitic acid: RN given refers to parent cpd; structure. pyromellitic acid : A tetracarboxylic acid that is benzene substituted by four carboxy groups at positions 1, 2, 4 and 5 respectively.	2.31	1	benzoic acids; tetracarboxylic acid
chloranil Chloranil: A quinone fungicide used for treatment of seeds and foliage.. tetrachloro-1,4-benzoquinone : A member of the class of 1,4-benzoquiones that is 1,4-benzoquinone in which all four hydrogens are substituted by chlorines.	2.31	1	1,4-benzoquinones; organochlorine compound	EC 2.7.1.33 (pantothenate kinase) inhibitor; metabolite
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.31	1	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
dithiol dithiol: structure	2.31	1
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	2.31	1	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.31	1	abietane diterpenoid; monocarboxylic acid	plant metabolite
4-(dimethylamino)benzoic acid [no description available]	2.31	1
agaric acid agaric acid: adenine nucleotide translocase antagonist	2.31	1
phenethyl isothiocyanate phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.	2.31	1	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite
1,2-benzisothiazoline-3-one 1,2-benzisothiazoline-3-one: a preservative in water-based solutions such as paints, cutting fluids, printing inks, cleaning agents, polyvinyl chloride gloves, etc.. benzo[d]isothiazol-3-one : An organic heterobicyclic compound based on a fused 1,2-thiazole and benzene bicyclic ring skeleton, with the S atom positioned adjacent to one of the positions of ring fusion.	2.31	1	organic heterobicyclic compound; organonitrogen heterocyclic compound	disinfectant; drug allergen; environmental contaminant; platelet aggregation inhibitor; sensitiser; xenobiotic
zinc ethylphenyldithiocarbamate [no description available]	2.31	1
baicalin [no description available]	2.31	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.	2.31	1	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger
vanitiolide [no description available]	2.31	1	methoxybenzenes; phenols
LSM-4272 [no description available]	2.31	1	beta-carbolines
rosiglitazone [no description available]	2.55	2	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
lopinavir [no description available]	2.31	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.31	1
tingenone tingenone: quinonoid triterpene isolated from Euonymus tingens	2.31	1
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.31	1	abietane diterpenoid	anticoronaviral agent
celastrol [no description available]	2.31	1	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	2.31	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
celastrol methyl ester celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME	2.31	1	carboxylic ester
miltirone miltirone: from Salvis miltiorrhiza Bunge; central benzodiazepine receptor ligand; structure given in first source	2.31	1	abietane diterpenoid
cryptotanshinone cryptotanshinone: from Salvia miltiorrhiza	2.31	1	abietane diterpenoid	anticoronaviral agent
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.31	1	abietane diterpenoid
2-phenyl-1,2-benzisothiazol-3-(2h)-one 2-phenyl-1,2-benzisothiazol-3-(2H)-one: structure given in first source; sulfur analog of ebselen	2.31	1
carboxyebselen carboxyebselen: a nitric oxide synthase inhibitor	2.31	1
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	2.31	1	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
1-methylpropyl-2-imidazolyl disulfide 1-methylpropyl-2-imidazolyl disulfide: a thioredoxin inhibitor with antineoplastic activity	2.31	1	imidazoles
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.61	2
nsc 95397 [no description available]	2.31	1	1,4-naphthoquinones
nsc 663284 NSC 663284: structure in first source	2.31	1	quinolone
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	2.31	1	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
ferruginol ferruginol: structure in first source. ferruginol : An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12.	2.31	1	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent
isopimaric acid isopimaric acid: isolated from the bark of Illicium jadifengpi	2.31	1	carbotricyclic compound; diterpenoid; monocarboxylic acid
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	2.31	1	aldehyde; tripeptide	cysteine protease inhibitor
docosahexaenoate efalex: a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement. docosahexaenoic acid : Any C22 polyunsaturated fatty acid containing six double bonds.. docosahexaenoate : A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.. all-cis-docosa-4,7,10,13,16,19-hexaenoic acid : A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.	2.07	1	docosahexaenoic acid; omega-3 fatty acid	algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical
gw 3965 GW 3965: a liver X receptor ligand	2.31	1	diarylmethane
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.31	1	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.31	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide [no description available]	2.31	1	indolecarboxamide	anticoronaviral agent
1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source	2.31	1	methoxybenzenes
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.31	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	2.31	1	cinnamate ester; tannin	food component; plant metabolite
5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine [no description available]	2.31	1	sulfonic acid derivative	anticoronaviral agent
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate [no description available]	2.31	1	acetylenic compound; furans; organofluorine compound; thioester; triazoles
telaprevir [no description available]	2.31	1	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide [no description available]	2.31	1	aromatic amide; furans	anticoronaviral agent
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.17	1	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
8-(Trifluoromethyl)-9H-purin-6-amine [no description available]	2.31	1	6-aminopurines	anticoronaviral agent
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.31	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
suramin sodium suramin(6-) : An organosulfate oxoanion that is the hexanion of suramin resulting from the deprotonation of the six sulfo groups; major species at pH 7.3.	2.31	1	organosulfate oxoanion
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	2.31	1	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.31	1	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
ginkgetin ginkgetin: from Cephalotaxus drupacea; biflavone; active against HSV-1; structure given in first source. ginkgetin : A biflavonoid that is the 7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2.	2.31	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	anti-HSV-1 agent; antineoplastic agent; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite
quercetin [no description available]	2.31	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.31	1	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	2.31	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
amentoflavone [no description available]	2.31	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
baicalein [no description available]	2.31	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
sciadopitysin sciadopitysin: biflavonoid from Taxus celebica & Ginkgo biloba. sciadopitysin : A biflavonoid that is a 7, 4', 4'''-trimethyl ether derivative of amentoflavone.	2.31	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	bone density conservation agent; platelet aggregation inhibitor
scutellarein scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.	2.31	1	tetrahydroxyflavone	metabolite
benzyloxycarbonyl-phe-ala-fluormethylketone cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).	2.31	1
bilobetin bilobetin: a phospholipase A2 antagonist	2.31	1	flavonoid oligomer
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.31	1	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
cinanserin Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity.. cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication.	2.31	1	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide : A tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2.	2.31	1	benzyl ester; isoxazoles; pyrrolidin-2-ones; tripeptide	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate [no description available]	2.31	1	dipeptide	anticoronaviral agent
mdl 201053 MDL 201053: Immunosuppressive Agent; RN given refers to compound with no isomeric designation	2.31	1
5-Chloro-3-pyridinyl 2-furoate [no description available]	2.31	1	carboxylic ester	anticoronaviral agent
sp 100030 N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide: transcription factor inhibitor specific to T-cells	2.31	1
gw0742 GW 610742: structure in first source	2.63	2	monocarboxylic acid
benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal: inhibits chymotrypsin activity of the proteasome	2.31	1
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.31	1	organic cation
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.31	1	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
triptohypol C triptohypol C : A pentacyclic triterpenoid with formula C29H40O4, originally isolated from the root bark of Tripterygium regelii.	2.31	1	benzenediols; monocarboxylic acid; pentacyclic triterpenoid	apoptosis inducer; plant metabolite
2-(4-chlorophenyl)-1,2-benzothiazol-3-one [no description available]	2.31	1	benzothiazoles
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	2.31	1	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
Dihydrotanshinone I dihydrotanshinone I: extracted from Radix Salviae	2.31	1	abietane diterpenoid	anticoronaviral agent
mk-0893 [no description available]	2.31	1
gw9508 GW9508: structure in first source	2.49	2	aromatic amine
Benzotriazol-1-yl 1H-indole-5-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
tannins gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).	2.31	1	tannin
oritavancin oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.	2.31	1	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent
exenatide [no description available]	2.08	1
5-Bromopyridin-3-yl furan-2-carboxylate [no description available]	2.31	1	carboxylic ester	anticoronaviral agent
(5-Chloropyridin-3-yl) 1H-indole-5-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
5-Chloropyridin-3-yl 1H-indole-2-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
phenylmercuric acetate Phenylmercuric Acetate: A phenyl mercury compound used mainly as a fungicide. Has also been used as a herbicide, slimicide, and bacteriocide.	2.31	1	arylmercury compound; benzenes
thimerosal Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.	2.31	1	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen
tak-875 [no description available]	5.34	9	biphenyls
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate [no description available]	2.31	1	dipeptide	anticoronaviral agent
N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide [no description available]	2.31	1	aromatic amide; furans
tug-469 TUG-469: a GPR40 agonist with antidiabetic activity; structure in first source	2.49	2
am 1638 [no description available]	3.03	4
bictegravir bictegravir: HIV Integrase Inhibitors. bictegravir : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1.	2.31	1	monocarboxylic acid amide; organic heterotetracyclic compound; secondary carboxamide; trifluorobenzene	HIV-1 integrase inhibitor
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.31	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
amg531 [no description available]	2.31	1
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM).	2.31	1	aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-fluoro-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.72 muM).	2.31	1	aldehyde; indolecarboxamide; monofluorobenzenes; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor

Condition	Relationship Strength	Studies
Diabetes Mellitus, Adult-Onset [description not available]	4.75	6
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	4.75	6
Alloxan Diabetes [description not available]	2.55	2
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

amg-837

Description

Cross-References

Synonyms (31)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (28)

Molecular Functions (23)

Ceullar Components (7)

Bioassays (128)

Research

Studies (24)

Market Indicators

Research Demand Index: 18.94

Study Types

amg-837

Description

Cross-References

Synonyms (31)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (6)

Inhibition Measurements

Activation Measurements

Biological Processes (28)

Molecular Functions (23)

Ceullar Components (7)

Bioassays (128)

Research

Studies (24)

Market Indicators

Research Demand Index: 18.94

Study Types

Related Drugs (125)

Related Conditions (6)